Ovagen (EDL Tripeptide): A Khavinson Bioregulator with Reported Hepatic and GI-Mucosal Activity

Research summary. Ovagen is a synthetic tripeptide bioregulator (Glu-Asp-Leu, EDL) developed within the Khavinson short-peptide bioregulator programme, with reported tissue tropism for the liver and gastrointestinal tract. It is not to be confused with another product marketed under a similar name containing ovine follicle-stimulating hormone (FSH), which is an entirely different biological entity used in reproductive medicine. Within the Khavinson framework, Ovagen sits alongside other tissue-tropic short peptides (Cardiogen, Bronchogen, Cortagen, Pinealon, Vesugen) and shares the family's general profile: extensive Russian-programme literature, limited independent Western replication, and proposed mechanisms involving direct gene-expression modulation that remain controversial in mainstream peptide pharmacology.

Molecular profile

• Sequence: Glu-Asp-Leu (EDL)
• Molecular formula: C₁₅H₂₅N₃O₈
• Molecular weight: ~375.4 g/mol
• PubChem CID: 444128
• Class: Khavinson short-peptide bioregulator — hepatic / GI-mucosal tropism
• Important nomenclature note: "Ovagen" is also used as a trade name for ovine FSH preparations in some markets. The two products are unrelated. This post addresses only the Khavinson tripeptide EDL.

Mechanism of action

Within the Khavinson bioregulator framework, Ovagen is reported to act through several proposed mechanisms:

• Tissue-specific gene-expression modulation. Reported direct interaction with promoter regions in liver and GI-mucosal tissue, with downstream effects on transcription of genes related to hepatocyte survival, fibrogenesis, and mucosal-barrier maintenance.
• Anti-fibrotic activity in hepatic models. Reductions in markers of hepatic stellate-cell activation and reductions in fibrosis progression have been reported in rodent liver-injury models.
• GI-mucosal-barrier maintenance. Reports include preservation of mucosal-layer integrity under stressors including antibiotic exposure, chemotherapy, and toxin exposure in rodent GI models.
• HIV-1 protease inhibition. A separate line of in vitro work has reported that the EDL tripeptide displays HIV-1 protease inhibitory activity at micromolar concentrations, an unusual finding for a short peptide and one that has motivated continued mechanistic interest.

The proposed direct chromatin / promoter-binding mechanism for an unmodified tripeptide remains controversial in mainstream peptide pharmacology. Pharmacokinetic data — bioavailability, plasma stability, tissue distribution — for unmodified short peptides like Ovagen suggest rapid clearance, which complicates interpretation of the proposed direct genomic mechanism.

Preclinical research highlights

Hepatic fibrosis models. Rodent liver-injury research (carbon tetrachloride, bile-duct ligation, and related models) has reported that Ovagen administration is associated with reductions in fibrosis markers (collagen deposition, α-smooth muscle actin staining of activated stellate cells) and with improvements in standard hepatic function parameters.

GI-mucosal-protection models. Rodent studies have reported preservation of GI-mucosal architecture under stressors including antibiotic-induced dysbiosis, chemotherapy-induced enteritis, and toxin exposure. These findings have driven Russian-programme interest in Ovagen as a candidate research peptide for mucosal protection in oncology and post-antibiotic recovery contexts.

HIV-1 protease inhibition in vitro. The reported HIV-1 protease inhibitory activity has been characterised in cell-free assays at micromolar concentrations. This finding has not advanced into clinical-stage HIV antiviral development; modern HIV protease inhibitors (e.g. darunavir, atazanavir, lopinavir) are nanomolar-affinity small molecules with much higher potency.

Aging-biology endpoints. Within the broader Khavinson framework, Ovagen has been reported to engage age-related DNA-condensation and gene-expression changes in liver and GI-mucosal cells, with effects framed as restoration toward younger-tissue baselines. These claims are part of the broader bioregulator literature whose key mechanistic features remain incompletely independently replicated.

Limitations of the evidence base

As with the broader Khavinson bioregulator family, important caveats apply:

• The supporting biological literature is concentrated within a single research programme, with limited independent Western replication.
• The proposed direct chromatin / promoter-binding mechanism for an unmodified short peptide remains controversial.
• Pharmacokinetic characterisation of Ovagen in vivo is sparse in publicly available literature.
• The HIV-1 protease inhibitory activity reported in vitro is at micromolar concentrations, several orders of magnitude weaker than approved HIV-protease-inhibitor drugs.
• No registered Phase 2 or Phase 3 clinical-trial programmes for Ovagen appear in major Western trial registries at the time of writing.

Current research status

Ovagen is an investigational research peptide. It is not approved by the FDA or EMA. Within the Khavinson research programme it sits among the family's tissue-tropic short peptides; outside that programme, independent research remains modest.

For research-supplier contexts, Ovagen is supplied as a research-grade investigational peptide and is not intended for self-administration. For broader context on the Khavinson bioregulator family and the methodological caveats that apply, see the separate posts on Epithalon, Cardiogen, Cortagen, and other family members.

Key takeaways for researchers

• Ovagen is a Khavinson tripeptide bioregulator (EDL, Glu-Asp-Leu) reported to display tissue tropism for the liver and gastrointestinal tract.
• Reported preclinical effects include reductions in hepatic fibrosis, GI-mucosal-barrier maintenance, and (separately) in vitro HIV-1 protease inhibition at micromolar concentrations.
• The proposed direct gene-expression-modulating mechanism for an unmodified short peptide remains controversial in mainstream peptide pharmacology.
• Supporting literature is concentrated in a single Russian research programme with limited independent Western replication.
• "Ovagen" is also the trade name of an unrelated ovine FSH product; the two are different molecules and should not be confused.
• Ovagen is not an approved therapeutic.

References

1. Khavinson VK, Lin'kova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2014;156(6):734–737.
2. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149.

---

This article is provided for educational and research purposes only. Ovagen is a research peptide. It is not an FDA- or EMA-approved drug and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.